Gep5 model for multiple myeloma
AssigneeBoard of Trustees of the University of Arkansas
InventorsBart BARLOGIE, Pingping QU, Christoph HEUCK, Joshua EPSTEIN
Life of this patent
Estimating the term…
Abstract
The invention provides, inter alia, methods of prognosing a subject with, or suspected of having, multiple myeloma. In certain embodiments, the methods entail testing the gene expression levels of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP 13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4) in a biological sample isolated from the subject. The invention also provides methods of treatment for multiple myeloma, as well as kits, oligonucleotides, and systems for performing the methods provided by the invention.
Claims37
A method of prognosing a subject suspected of having multiple myeloma, comprising:
- testing the gene expression levels of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4) in a biological sample isolated from the subject using a method capable of detecting the expression levels of the genes when the biological sample comprises about 50,000 or fewer myeloma cells;
- and
- quantifying the gene expression levels of each of ENO1, FABP5, TRIP13, TAGLN2, and RFC4,
- wherein an abnormal gene expression profile as compared to a suitable control is associated with a poor prognosis for the subject.
A method of prognosing progression free survival (PFS) in a subject with multiple myeloma undergoing Total Therapy 3b (TT3b), comprising:
- testing the gene expression levels of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4) in a biological sample isolated from the subject;
- and
- quantifying the gene expression levels of each of ENO1, FABP5, TRIP13, TAGLN2, and RFC4,
- wherein an abnormal gene expression profile is associated with a reduced likelihood of PFS for the subject.
A method of prognosing progression free survival (PFS) or overall survival (OS) in a subject with multiple myeloma undergoing Total Therapy 4 (TT4) or Total Therapy 5 (TT5), comprising:
- testing the gene expression levels of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4) in a biological sample isolated from the subject;
- and
- quantifying the gene expression levels of each of ENO1, FABP5, TRIP13, TAGLN2, and RFC4,
- wherein an abnormal gene expression profile is associated with a reduced likelihood of PFS or OS for the subject.
A method of prognosing a subject suspected of having multiple myeloma, comprising:
- testing, by qRT-PCR, the nucleic acid gene expression levels of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4) in a nucleic acid sample isolated from a biological sample isolated from the subject;
- and
- calculating the mean, log-normalized gene expression level of ENO1, FABP5, TRIP13, TAGLN2, and RFC4,
- wherein an elevated mean, log-normalized gene expression level of ENO1, FABP5, TRIP13, TAGLN2, and RFC4, relative to a suitable control, is associated with a poor prognosis for the subject.
A non-transitory computer-readable storage medium that provides instructions that, if executed by a processor, causes the processor to perform operations comprising:
- reading data representing the gene expression levels of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4) determined for an isolated biological sample obtained from a subject;
- analyzing the data to determine the presence of an abnormal gene expression profile as compared to a suitable control;
- and
- providing a classification of the subject on the basis of the data analysis, wherein the presence of an abnormal gene expression profile is associated with a poor prognosis for the subject.
Dependencies are inferred from the claim text.